183 related articles for article (PubMed ID: 34675932)
1. NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma.
Orrantia A; Terrén I; Astarloa-Pando G; González C; Uranga A; Mateos-Mazón JJ; García-Ruiz JC; Riñón M; Rey M; Pérez-Fernandez S; Zenarruzabeitia O; Borrego F
Front Immunol; 2021; 12():748207. PubMed ID: 34675932
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma.
Tognarelli S; Wirsching S; von Metzler I; Rais B; Jacobs B; Serve H; Bader P; Ullrich E
Front Immunol; 2018; 9():2743. PubMed ID: 30542346
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma.
Rueff J; Medinger M; Heim D; Passweg J; Stern M
Biol Blood Marrow Transplant; 2014 Jun; 20(6):896-9. PubMed ID: 24631739
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
[TBL] [Abstract][Full Text] [Related]
5. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
6.
Orrantia A; Vázquez-De Luis E; Astarloa-Pando G; Terrén I; Amarilla-Irusta A; Polanco-Alonso D; González C; Uranga A; Carrascosa T; Mateos-Mazón JJ; García-Ruiz JC; Callejas S; Quintas A; Dopazo A; Zenarruzabeitia O; Borrego F
iScience; 2022 Oct; 25(10):105235. PubMed ID: 36262311
[TBL] [Abstract][Full Text] [Related]
7. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
Shi J; Tricot G; Szmania S; Rosen N; Garg TK; Malaviarachchi PA; Moreno A; Dupont B; Hsu KC; Baxter-Lowe LA; Cottler-Fox M; Shaughnessy JD; Barlogie B; van Rhee F
Br J Haematol; 2008 Dec; 143(5):641-53. PubMed ID: 18950462
[TBL] [Abstract][Full Text] [Related]
8. Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group.
Drozd-Sokołowska J; Waszczuk-Gajda A; Topczewska M; Mańko J; Hus I; Szmigielska-Kapłon A; Nowicki M; Grygoruk-Wiśniowska I; Krawczyk-Kuliś M; Romejko-Jarosińska J; Frączak E; Wróbel T; Piątkowska-Jakubas B; Mądry K; Boguradzki P; Król M; Kozioł M; Hus M; Kopińska A; Dmoszyńska A; Basak GW; Dwilewicz-Trojaczek J
J Clin Apher; 2021 Jun; 36(3):443-453. PubMed ID: 33592119
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas.
Porrata LF; Inwards DJ; Micallef IN; Johnston PB; Ansell SM; Hogan WJ; Markovic SN
Clin Dev Immunol; 2010; 2010():914945. PubMed ID: 20414345
[TBL] [Abstract][Full Text] [Related]
10. The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma.
Krause DS; Spitzer TR; Stowell CP
Arch Pathol Lab Med; 2010 Jul; 134(7):1033-8. PubMed ID: 20586634
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
12. The importance of the number of transplanted cells with dipeptidyl peptidase-4 expression on the haematopoietic recovery and lymphocyte reconstitution in patients with multiple myeloma after autologous haematopoietic stem-cell transplantation.
Kopinska A; Krawczyk-Kulis M; Dziaczkowska-Suszek J; Bieszczad K; Jagoda K; Kyrcz-Krzemien S
Hematol Oncol; 2017 Jun; 35(2):225-231. PubMed ID: 28620928
[TBL] [Abstract][Full Text] [Related]
13. Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation.
Richter S; Böttcher M; Stoll A; Zeremski V; Völkl S; Mackensen A; Ekici AB; Jacobs B; Mougiakakos D
Transplant Cell Ther; 2024 Jun; 30(6):628.e1-628.e9. PubMed ID: 38460727
[TBL] [Abstract][Full Text] [Related]
14. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect.
Nguyen S; Dhedin N; Vernant JP; Kuentz M; Al Jijakli A; Rouas-Freiss N; Carosella ED; Boudifa A; Debré P; Vieillard V
Blood; 2005 May; 105(10):4135-42. PubMed ID: 15687235
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
[TBL] [Abstract][Full Text] [Related]
16. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
González-Calle V; Cerdá S; Labrador J; Sobejano E; González-Mena B; Aguilera C; Ocio EM; Vidriales MB; Puig N; Gutiérrez NC; García-Sanz R; Alonso JM; López R; Aguilar C; de Coca AG; Hernández R; Hernández JM; Escalante F; Mateos MV
Haematologica; 2017 May; 102(5):922-931. PubMed ID: 28126960
[TBL] [Abstract][Full Text] [Related]
17. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells.
Bigley AB; Rezvani K; Chew C; Sekine T; Pistillo M; Crucian B; Bollard CM; Simpson RJ
Brain Behav Immun; 2014 Jul; 39():160-71. PubMed ID: 24200514
[TBL] [Abstract][Full Text] [Related]
18. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
19. Naive Donor NK Cell Repertoires Associated with Less Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Björklund AT; Clancy T; Goodridge JP; Béziat V; Schaffer M; Hovig E; Ljunggren HG; Ljungman PT; Malmberg KJ
J Immunol; 2016 Feb; 196(3):1400-11. PubMed ID: 26746188
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
Shilling HG; McQueen KL; Cheng NW; Shizuru JA; Negrin RS; Parham P
Blood; 2003 May; 101(9):3730-40. PubMed ID: 12511415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
